U.S. markets open in 9 hours 11 minutes
  • S&P Futures

    3,753.50
    -3.25 (-0.09%)
     
  • Dow Futures

    29,969.00
    -13.00 (-0.04%)
     
  • Nasdaq Futures

    11,535.50
    -6.25 (-0.05%)
     
  • Russell 2000 Futures

    1,759.30
    +1.20 (+0.07%)
     
  • Crude Oil

    88.41
    -0.04 (-0.05%)
     
  • Gold

    1,718.30
    -2.50 (-0.15%)
     
  • Silver

    20.77
    +0.11 (+0.53%)
     
  • EUR/USD

    0.9807
    +0.0012 (+0.12%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1173
    +0.0005 (+0.04%)
     
  • USD/JPY

    144.9450
    -0.1230 (-0.08%)
     
  • BTC-USD

    20,006.37
    -384.90 (-1.89%)
     
  • CMC Crypto 200

    455.32
    -7.80 (-1.68%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,127.93
    -183.37 (-0.67%)
     

Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments

·1 min read
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca Plc's (NASDAQ: AZN) Ultomiris (ravulizumab) for generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

  • Ultomiris would be the first and only approved long-acting C5 complement inhibitor for AChR antibody-positive gMG in the EU if authorized.

  • The positive opinion is based on results from the CHAMPION-MG Phase 3 trial, in which Ultomiris was superior to placebo on a patient-reported scale that assesses patients' abilities to perform daily activities.

  • Ultomiris was approved in the U.S. in April for adults with gMG who are AChR antibody-positive, and regulatory reviews are ongoing in additional countries, including Japan.

  • The CHMP has also backed AstraZeneca's Tezspire (tezepelumab) as add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high-dose inhaled corticosteroids and other maintenance treatment.

  • Tezspire was approved as an add-on maintenance treatment of severe asthma in the U.S. in December 2021.

  • Price Action: AZN shares are up 1.64% at $66.32 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.